Product information and disease descriptionProduct descriptionProduct information
Effect of Barzolvolimab on quality measures
4 evidence topics · 4 sources
AAAAI and ACAAI urticaria measures: laboratory test overuse and antihistamine updosing underuse
Recommendation against routine extensive testing in chronic urticaria
Physician adherence to CSU guidelines in a multinational online survey of dermatologists and allergists, Novartis-funded
“This is a multinational cross-sectional online survey involving patients with CSU and CSU-treating physicians from seven countries (USA, Canada, UK, Germany, France, Italy, and Japan).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Overall, 862 physicians (517 dermatologists; 345 allergists) participated in the study.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Globally, 56% of physicians adhered to guidelines, 19% followed therapeutic protocols, and approximately 30% did not adhere to any guideline.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“This study and the journal’s Rapid Service Fees were funded by Novartis Pharma AG, Basel, Switzerland.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Physician awareness of and adherence to CSU guidelines, Genentech-funded study
“Finally, some physicians are not aware of, or do not adhere to, international guidelines available for the treatment of CSU.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“This study was funded by Genentech, Inc, a member of the Roche Group.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Product-specific effect on quality measures
No evidence found.